HRMY
Harmony Biosciences Holdings, Inc.
HRMY trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over HRMY overall, supported by stronger fundamentals and stronger modeled upside.
HRMY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
HRMY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HRMY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.7x | $33.80 | — |
| Cheap | 11x | $33.44 | -1.1% |
| Current | 11x | $33.80 | — |
| Fair | 13x | $39.95 | +18% |
| Expensive | 22x | $66.11 | +96% |
Historical ranges are pointers, not guarantees.
HRMY has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HRMY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for HRMY, but weaker profitability. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over HRMY on the outlook, with more favorable profitability expectations.
HRMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.90 | +29% |
| Q3 2026 | $3.02 | -5% |
| Q2 2026 | $3.08 | -0.6% |
| Q1 2026 | $2.48 | -5.3% |
| Q4 2025 | $2.71 | +8% |
| Q3 2025 | $3.18 | +50% |
| Q2 2025 | $3.10 | +58% |
| Q1 2025 | $2.62 | +13% |
| Q4 2024 | $2.51 | +18% |
HRMY earned $3.02 per share over the past year, down 5% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HRMY on earnings, with more consistent year-over-year improvement.
HRMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.9M | +12% |
| Q2 2026 | $261.3M | +30% |
| Q1 2026 | $215.4M | +17% |
| Q4 2025 | $243.8M | +21% |
| Q3 2025 | $239.5M | +29% |
| Q2 2025 | $200.5M | +16% |
| Q1 2025 | $184.7M | +19% |
| Q4 2024 | $201.3M | +20% |
HRMY's revenue has grown year over year every quarter since late 2020: $269M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -7.2 points |
| Q2 2026 | 34% | +10 points |
| Q1 2026 | 17% | -13 points |
| Q4 2025 | 16% | -12 points |
| Q3 2025 | 27% | -5.8 points |
| Q2 2025 | 24% | +12 points |
| Q1 2025 | 30% | -3.2 points |
| Q4 2024 | 28% | +3.8 points |
HRMY's operating margin was 20% last quarter, down 7.2 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HRMY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HRMY on profitability, with a higher operating margin.
HRMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $126M | +68% |
| Q3 2025 | $108.7M | +54% |
| Q2 2025 | $79.3M | +89% |
| Q1 2025 | $33.9M | +8.7% |
| Q4 2024 | $75M | -2% |
| Q3 2024 | $70.5M | +12% |
| Q4 2023 | $76.6M | +187% |
| Q3 2023 | $63.1M | +14% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with HRMY at up 128%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
HRMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +924K shares |
| 1 year | +1.6% | +961K shares |
| 3 years | -1.7% | -1M shares |
| 5 years | +3.4% | +2M shares |
| Available history | +8% | +4.4M shares |
HRMY has 60M diluted shares, up 1.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $50M |
| Q4 2020 | — |
| Q2 2020 | $167,000 |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HRMY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HRMY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -1.4x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
| Q2 2024 | -0.7x | Net Cash |
| Q1 2024 | -0.6x | Net Cash |
| Q4 2023 | -0.6x | Net Cash |
HRMY has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HRMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 23.6 | Neutral |
HRMY's weekly RSI is 44 (neutral) and its Stochastic is 24 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HRMY PE vs Healthcare Sector
| Metric | HRMY | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
| PE % | 18 | 32 | 14 pts below |
HRMY has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HRMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.6 | 10% below |
| 20 week MA | $38.0 | 11% below |
| 50 week MA | $35.0 | 3.4% below |
| 100 week MA | $34.2 | 1.2% below |
| 200 week MA | $34.0 | 0.7% below |
HRMY is in a downtrend: it's below all five of its weekly moving averages, and 0.7% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HRMY on trend strength, trading above more of its moving averages.
HRMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.0 | $36.5 | +1.3% |
| 2021 | $36.5 | $43.9 | +20% |
| 2022 | $43.9 | $56.7 | +29% |
| 2023 | $56.7 | $32.3 | -43% |
| 2024 | $32.3 | $34.2 | +5.9% |
| 2025 | $34.2 | $38.1 | +11% |
| 2026 YTD | $38.1 | $33.8 | -11% |
HRMY has finished higher in five of the last six years. It's down 11% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HRMY on returns for 2026, with the stronger performance.